Medtech Myth Busting: The Edwards Enigma Deepens The recent upgrade of Edwards Lifesciences by Leerink Partners analyst Mike Kratky has raised more questions than answers about the company's prospects in the medtech space.
Dubbed "the cleanest large cap medtech story" by some, Edwards' performance has been nothing short of impressive.
However, beneath this surface level success lies a complex web of challenges that threaten to undermine its growth.